JPRN-UMIN000014445已完成未知
Clinical efficacy of Eribulin new for metastatic breast cancer - Clinical efficacy of Eribulin new for metastatic breast cancer
Graduate School of Medicine and Faculty of Medicine, the University of Tokyo0 个研究点目标入组 120 人开始时间: 2014年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who sustain adverse events using after taxanes. Patients who have not enough judgment ability minors, in adults, cases of acquisition agreement by the description document is difficult. Patients who are subjected to treatment without their doctors not revealing the breast cancer treatment.
研究者
相似试验
已完成
2 期
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerMetastatic Breast CancerNCT05206656Hunan Cancer Hospital80
已完成
2 期
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
已完成
2 期
Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression.Advanced or metastatic breast cancerJPRN-UMIN000006086Dept. Surgical Oncology, Osaka City University Graduate School of Medicine35
撤回
2 期
Eribulin in Brain Metastases From HER2-negative Breast CancerMetastatic Breast CancerNCT03637868Institut Paoli-Calmettes